DK1858490T3 - Lægemiddelformer med forbedrede farmakokinetiske egenskaber - Google Patents

Lægemiddelformer med forbedrede farmakokinetiske egenskaber

Info

Publication number
DK1858490T3
DK1858490T3 DK06706994.8T DK06706994T DK1858490T3 DK 1858490 T3 DK1858490 T3 DK 1858490T3 DK 06706994 T DK06706994 T DK 06706994T DK 1858490 T3 DK1858490 T3 DK 1858490T3
Authority
DK
Denmark
Prior art keywords
pharmacokinetic properties
pharmaceutical forms
improved pharmacokinetic
improved
pharmaceutical
Prior art date
Application number
DK06706994.8T
Other languages
English (en)
Inventor
Peter Serno
Roland Heinig
Kerstin Pauli
Yutaka Hayauchi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36264023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1858490(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK1858490T3 publication Critical patent/DK1858490T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK06706994.8T 2005-03-01 2006-02-16 Lægemiddelformer med forbedrede farmakokinetiske egenskaber DK1858490T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005009240A DE102005009240A1 (de) 2005-03-01 2005-03-01 Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
PCT/EP2006/001393 WO2006092207A1 (de) 2005-03-01 2006-02-16 Arzneiformen mit verbesserten pharmakokinetischen eigenschaften

Publications (1)

Publication Number Publication Date
DK1858490T3 true DK1858490T3 (da) 2012-07-23

Family

ID=36264023

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06706994.8T DK1858490T3 (da) 2005-03-01 2006-02-16 Lægemiddelformer med forbedrede farmakokinetiske egenskaber

Country Status (39)

Country Link
US (2) US8613950B2 (da)
EP (2) EP2377523A1 (da)
JP (1) JP5122984B2 (da)
KR (1) KR101360526B1 (da)
CN (2) CN101141950B (da)
AR (2) AR053552A1 (da)
AT (1) ATE552828T1 (da)
AU (1) AU2006220100B2 (da)
BR (1) BRPI0609375A2 (da)
CA (1) CA2599617C (da)
CR (2) CR9339A (da)
CY (1) CY1112874T1 (da)
DE (1) DE102005009240A1 (da)
DK (1) DK1858490T3 (da)
DO (1) DOP2006000049A (da)
ES (1) ES2384109T3 (da)
GT (1) GT200600097A (da)
HK (1) HK1118457A1 (da)
HN (1) HN2006009000A (da)
HR (1) HRP20120545T1 (da)
IL (2) IL185552A (da)
MA (1) MA29376B1 (da)
MX (1) MX2007010527A (da)
MY (2) MY177386A (da)
NO (2) NO332368B1 (da)
NZ (1) NZ561004A (da)
PE (2) PE20061015A1 (da)
PL (1) PL1858490T3 (da)
PT (1) PT1858490E (da)
RS (1) RS52374B (da)
RU (2) RU2423970C2 (da)
SG (1) SG160330A1 (da)
SI (1) SI1858490T1 (da)
TN (1) TNSN07336A1 (da)
TW (1) TWI387465B (da)
UA (1) UA93200C2 (da)
UY (1) UY29395A1 (da)
WO (1) WO2006092207A1 (da)
ZA (1) ZA200707320B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
DE102007027067A1 (de) 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
DE102009020888A1 (de) * 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
KR20120034643A (ko) 2009-05-20 2012-04-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 유핵형 구강 내 붕괴 정
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CN103372014B (zh) * 2012-04-26 2015-10-21 齐鲁制药有限公司 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法
CN102727455B (zh) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 一种他达那非口腔崩解片及其制备方法
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN110193015A (zh) * 2018-02-27 2019-09-03 广州朗圣药业有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
CN108272765B (zh) * 2018-04-26 2021-02-02 江西杏林白马药业股份有限公司 含盐酸伐地那非的药物组合物、口崩片及其制备、应用
US11648201B2 (en) 2018-05-02 2023-05-16 Ferring B.V. Pharmaceutical formulations
CN110840851A (zh) * 2019-08-16 2020-02-28 天津仁卫生物医药科技有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
IT201900020350A1 (it) 2019-11-05 2021-05-05 Alpex Pharma Sa Formulazione orodispersibile di vardenafil
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114848603B (zh) * 2022-04-25 2023-12-12 湖北菲瑞生物药业有限公司 一种伐地那非冻干闪释片及其制备工艺

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB790762A (en) 1953-08-28 1958-02-19 Arthur Poole A hydrate of lignocaine hydrochloride and process for making it
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (da) * 1963-01-16
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
EP0054132B1 (de) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US4939544A (en) * 1989-11-01 1990-07-03 Eastman Kodak Company Mask for radiation emitting panel
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
RU2101010C1 (ru) * 1990-04-11 1998-01-10 Дзе Апджон Компани Вкусовая маскировка ибупрофена полимерным покрытием
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
ES2386420T3 (es) * 1997-11-12 2012-08-20 Bayer Pharma Aktiengesellschaft Imidazotriazinonas sustituidas con fenilo en la posición 2 como inhibidores de fosfodiesterasas
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
PL356848A1 (en) * 1999-12-24 2004-07-12 Bayer Aktiengesellschaft Novel imidazo[1,3,5]triazinones and the use thereof
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
EP1330250B1 (en) * 2000-10-30 2004-05-12 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
JP4179784B2 (ja) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
ES2278927T3 (es) * 2001-05-09 2007-08-16 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas de 2-(2-etoxi-5-(4-metil-piperazin-1-sulfonil)-fenil)-5-metil-7-propil-3h-imidazo(5,1-f)(1,2,4)triazin-4-ona.
CN1473035B (zh) 2001-07-27 2012-07-18 安斯泰来制药有限公司 含有口腔内迅速崩解片剂用缓释微粒的组合物及其制造方法
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
AU2004246837B2 (en) 2003-06-06 2009-07-16 Ethypharm Orally-dispersible multilayer tablet
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
JP2007534771A (ja) 2004-04-27 2007-11-29 メディシノバ，インコーポレーテッド 炎症性疾患の治療におけるフェノキシアルキルカルボン酸誘導体
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP1817009A2 (en) 2004-11-24 2007-08-15 Spi Pharma, Inc. Orally disintegrating compositions
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
MX2008000087A (es) 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
WO2007029376A1 (ja) 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤

Also Published As

Publication number Publication date
GT200600097A (es) 2006-11-13
ATE552828T1 (de) 2012-04-15
AU2006220100A1 (en) 2006-09-08
US20080249096A1 (en) 2008-10-09
KR101360526B1 (ko) 2014-02-21
UA93200C2 (ru) 2011-01-25
IL185552A (en) 2017-06-29
NO344546B1 (no) 2020-01-27
HRP20120545T1 (hr) 2012-07-31
PE20061015A1 (es) 2006-10-20
MA29376B1 (fr) 2008-04-01
AU2006220100B2 (en) 2011-08-18
CA2599617A1 (en) 2006-09-08
BRPI0609375A2 (pt) 2010-03-30
PE20100740A1 (es) 2010-10-28
NO332368B1 (no) 2012-09-03
US20140186444A1 (en) 2014-07-03
JP5122984B2 (ja) 2013-01-16
RU2011111106A (ru) 2012-09-27
TWI387465B (zh) 2013-03-01
IL185552A0 (en) 2008-01-06
EP1858490B1 (de) 2012-04-11
DE102005009240A1 (de) 2006-09-07
RU2481110C2 (ru) 2013-05-10
CR20130381A (es) 2013-09-12
MX2007010527A (es) 2007-11-08
NO20120203L (no) 2007-09-27
MY148698A (en) 2013-05-31
ES2384109T3 (es) 2012-06-29
MY177386A (en) 2020-09-14
UY29395A1 (es) 2006-10-02
HK1118457A1 (en) 2009-02-13
EP2377523A1 (de) 2011-10-19
CN102198140A (zh) 2011-09-28
TW200640503A (en) 2006-12-01
CR9339A (es) 2007-12-17
WO2006092207A1 (de) 2006-09-08
CN101141950A (zh) 2008-03-12
AR053552A1 (es) 2007-05-09
PL1858490T3 (pl) 2012-09-28
RU2007135982A (ru) 2009-04-10
PT1858490E (pt) 2012-06-19
SG160330A1 (en) 2010-04-29
CN101141950B (zh) 2011-06-08
DOP2006000049A (es) 2006-10-31
HN2006009000A (es) 2010-08-05
IL246548A0 (en) 2016-08-31
NO20074848L (no) 2007-09-27
EP1858490A1 (de) 2007-11-28
KR20070110109A (ko) 2007-11-15
JP2008531614A (ja) 2008-08-14
RS52374B (en) 2012-12-31
AR111572A2 (es) 2019-07-31
RU2423970C2 (ru) 2011-07-20
ZA200707320B (en) 2009-08-26
US8613950B2 (en) 2013-12-24
SI1858490T1 (sl) 2012-07-31
NZ561004A (en) 2010-12-24
CY1112874T1 (el) 2016-04-13
TNSN07336A1 (en) 2008-12-31
CA2599617C (en) 2012-01-10
CN102198140B (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
DK1858490T3 (da) Lægemiddelformer med forbedrede farmakokinetiske egenskaber
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
DK1957073T3 (da) Lægemiddel
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
DK1885411T3 (da) Injektionsindretning
DK1888147T3 (da) Injektionsindretning
DK2194043T3 (da) Fremgangsmåder
DE602006010217D1 (de) N piconets
DE602006012066D1 (de) Daraus
ITRM20060613A1 (it) Treppiede perfezionato
DK1885966T3 (da) Forbedret hoved-t-forbindelse
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DK1856051T3 (da) Amorft lercanidipinhydrochlorid
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
DK1927646T3 (da) Odoriseringsmiddel med forbedret stabilitet
DE502006004022D1 (de) Einspritzdüse
DE602006009608D1 (de) Synchronisierungseinrichtung
DE502006001058D1 (de) Synchronisiereinrichtung
ITMI20062284A1 (it) Termofusibile
AT503395A3 (de) Plastifizierzylinder
DK1855695T3 (da) Fast farmaceutisk sammensætning med telithromycin
DE502006000618D1 (de) Einspritzdüse
ATE541837T1 (de) Oxaphenanthren-derivate